

PARTICIPATING FACULTY

New Approaches for the Management and Treatment of Migraine

This supplement to *The American Journal of Managed Care* contains information about new approaches for the management and treatment of migraine.

Faculty

Andrew Blumenfeld, MD

Director
The Headache Center of Southern California
Scripps Memorial Hospital-Encinitas
Encinitas, California

Gary M. Owens, MD

Vice President
Medical Management and Policy
Independence Blue Cross
Philadelphia, Pennsylvania

Lawrence D. Goldberg, MD, MBA

President
Goldberg, MD & Associates
Battle Ground, Washington

Disclosure Statement

In accordance with the ACCME and the ACPE, participants for this activity have completed a conflict-of-interest statement.

In compliance with the Health Insurance Portability and Accountability Act standards, no presentations in this CME/CE activity shall disclose the names or other identifiers of patients referenced without a signed waiver from the identified patient.

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

This participant has declared the following relationships with pharmaceutical organizations:

■ **Andrew Blumenfeld, MD**

Research/Grant Support From/Advisory Board For:

Allergan

Research Support From:

Medtronic

Speakers' Bureau For:

Pfizer

Ortho-McNeil

GlaxoSmithKline

This participant reports no relationships with pharmaceutical organizations:

■ **Gary M. Owens, MD**

Disclosure information for **Lawrence D. Goldberg, MD, MBA**, was not available at the time of publication.

NOTE: This supplement contains information about off-label usage of botulinum toxin for migraine prophylaxis. The discussion of botulinum toxin should not be construed as an endorsement of this therapeutic modality or of its manufacturer. The manufacturer is seeking approval from the US Food and Drug Administration (FDA) for the use of botulinum toxin for migraine pain. Currently, the drug is in phase 3 of clinical trials.

This supplement also includes discussion of epilepsy drugs. The reader should be aware that the FDA has recently requested manufacturers of epilepsy drugs to reexamine their clinical trial data in response to claims that such medications may increase the risk of suicide in some patients.